Session Details
Poster Oral Presentation 1
Fri. Jul 11, 2025 1:00 PM - 1:45 PM JST
Fri. Jul 11, 2025 4:00 AM - 4:45 AM UTC
Fri. Jul 11, 2025 4:00 AM - 4:45 AM UTC
Room Ⅶ (Makuhari Messe International Conference Room)(Makuhari Messe International Conference Room) 1
[PO-001]Induction efficacy and safety of upadacitinib for active Crohn’s disease in Japan
*Takuto Saiki1, Junji Umeno1, Yuichi Matsuno1, Tomohiro Nagasue1, Shin Fujioka1,2, Keisuke Kawasaki1, Tomohiko Moriyama1,3, Shinichi Kawano4, Shigeo Nakamura4, Kanami Ota5, Akira Harada5, Yoshiaki Nozaka6, Koichi Kurahara6, Takehiro Torisu1 (1. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., 2. Department of Endoscopic Diagnostics and Therapeutics, Kyushu University Hospital, Fukuoka, Japan., 3. Department of International Medical Department, Kyushu University Hospital, Fukuoka, Japan., 4. Division of gastroenterology, Steel Memorial Yawata Hospital, Kitakyushu, Japan., 5. Division of gastroenterology, Yamaguchi Red Cross Hospital, Yamaguchi, Japan., 6. Division of gastroenterology, Matsuyama Red Cross Hospital, Matsuyama, Japan.)
[PO-002]Clinical Outcomes of Upadacitinib in Crohn’s Disease: A Retrospective Observational Study from a Chinese Tertiary Center
*Chunyan Peng1, Chang Zheng1, Ying Xie1, Mo Wang1, Fan Zhou1, Xiaoqi Zhang1 (1. Affiliated Nanjing Drum Tower Hospital, and Medical School of Nanjing University)
[PO-003]Effectiveness and Safety of Upadacitinib in Refractory Crohn's Disease Patients: A Multicenter Study from China
*Zile Zhang1, Xiaoyan Duan2, Duowu Zou1, Yubei Gu1, Wensong Ge2 (1. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China, 2. Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine)
[PO-004]Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
Arshdeep Singh1, Arshia Bhardwaj1, Riya Sharma1, *Vandana Midha1, Ajit Sood1 (1. Dayanand Medical College and Hospital, Ludhiana, India)
[PO-005]Three Cases of Drug-Induced Lymphocyte Stimulation Test (DLST) Positivity in Ulcerative Colitis Patients Treated with Janus Kinase Inhibitors
*Keiji Yagisawa1, Yuya Ohno2, Shinsuke Otagiri2, Takahiro Ito2, Atsuo Maemoto2 (1. Department of Pharmacy, Sapporo Higashi Tokushukai Hospital, 2. Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital)
[PO-006]Time Course and Risk Assessment of Lipid Profile Alterations in Ulcerative Colitis Patients Receiving JAK Inhibitor Therapy: A Real-world Analysis
*Kento Shimizu1, Yuki Ohta1, Yoshiki Matsubara1, Takuya Ohashi1, Toshiyuki Ito1, Shohei Mukai1, Nobuaki Shu1, Yushi Koshibu1, Yusuke Oseki1, Hayato Nakazawa1, Yuhei Oyama1, Yukiyo Mamiya1, Ryosuke Horio1, Satsuki Takahashi1, Chihiro Goto1, Michiko Sonoda1, Tatsuya Kaneko1, Tsubasa Ishikawa1, Takashi Taida1, Kenichiro Okimoto1, Tomoaki Matsumura1, Jun Kato1 (1. Chiba University Hospital)
[PO-007]CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CHINESE BIOLOGICS EXPOSURE PATIENTS WITH CROHN’S DISEASE, SUBGROUP RESULTS FROM 2ND INTERIM ANALYSIS OF VALUE STUDY
Baili Chen1, Lan Zhong2, Yali Zhang3, Jinhai Wang4, Xiaoyu Qian5, *Fang Zhou5, Minhu Chen6 (1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 510080, 2. Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China, 3. Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.510515, 4. The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 710000, 5. Takeda Pharmaceutical Company, Shanghai, China. 200126, 6. The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 510062)
[PO-008]CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CHINESE BIO-NAIVE PATIENTS WITH ULCERATIVE COLITIS, SUBGROUP RESULTS FROM 2ND INTERIM ANALYSIS OF VALUE STUDY
Hong Yang1, Ye Chen2, Haiyan Zhang3, Yingchao Li4, Xueli Ding5, Lifei Gu6, *Fang Zhou6, Minhu Chen7 (1. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 100730, 2. Department of Gastroenterology, Integrated Clinical Microecology Center, Shenzhen Hospital, Southern Medical University, 1333 New Lake Road, Shenzhen, 518100, China., 3. Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.510120, 4. The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. 710000, 5. The Affiliated Hospital of Qingdao University, Qingdao, China. 266000, 6. Takeda Pharmaceutical Company, Shanghai, China. 200126, 7. The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 510062)
[PO-009]Short-term effectiveness of continued vedolizumab administration in patients with ulcerative colitis unresponsive to vedolizumab induction therapy
*Takashi Hashimoto1, Ryosuke Sakemi1, Suketo So1, Kohei Sugiyama2,3, Maki Miyakawa2, Masanao Nasuno2, Hiroki Tanaka2 (1. Department of Gastroenterology, Tobata Kyoritsu Hospital, 2. Sapporo IBD Clinic, 3. Department of Gastroenterology, Sapporo Central Hospital)
[PO-010]Generalized Urticaria After Switch Back to Intravenous Vedolizumab Following Injection Site Reactions to Subcutaneous Therapy: A Case Report
*Reikei Matsuda1, Kaori Imafuku1, Tomoya Orimo1, Yuuki Takeoka1, Yasuki Hori1, Asami Nishino1, Yuri Takagi1, Atsushi Yamamoto1 (1. Department of Gastroenterology, Fujisawa Shounandai Hospital)
[PO-011]Short term survey of the preference questionnaire of vedolizumab modalities in patients with ulcerative colitis
*Shingo Kato1, Kei Tagawa1, Kazutoshi Suzuki1 (1. Center for Inflammatory Bowel disease, Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University)